PMH72 MEDICATION PRESCRIBING PATTERNS FOR PATIENTS WITH BIPOLAR DEPRESSION  by deLay, N et al.
285Abstracts
underwent 3.6 distinct medication regimens with each, on
average, having 2 drugs. Poly-pharmacy (multiple drug combi-
nation) treatments represent 60% of the days of treatment and
a disproportionate 82% share of costs. Average paid cost per day
of treatment for those using poly-pharmacy is $7.56, whereas
monotherapy is $2.47. Twenty-three percent of patients are
treated with poly-pharmacy initially and permanently. Anti-
psychotics and benzodiazapine-based treatments are most com-
monly seen (80%) in poly-pharmacy treatments. Increasing
severity of illness is related to increased poly-pharmacy, with the
exception of those patients in remission. CONCLUSION: Phar-
macologic treatment of bipolar is challenging, individualized and
characterized by poly-pharmacy, reﬂecting the cyclical nature of
the disorder. The impact of the complexity of treating bipolar
needs to be studied to determine how service utilization and costs
are inﬂuenced.
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OBJECTIVE: In part because of its cyclical nature, bipolar dis-
order is frequently missed or misdiagnosed in clinical practice.
Over one third of bipolar patients report a period of 10+ years
between initially seeking treatment and proper diagnosis. Under-
standing when and where bipolar disorder is being diagnosed
represents an important step for targeting efforts to improve the
accurate identiﬁcation of bipolar patients. METHODS: To
examine characteristics of initial bipolar diagnosis, the Phar-
Metrics Integrated Outcomes Database of adjudicated medical
and pharmaceutical claims for over 3 million patients from 11
U.S. health plans was utilized. We identiﬁed 3,648 bipolar
patients based on the following criteria: two claims with ICD-9-
CM diagnosis for bipolar disorder (296.0, 296.1, 296.4–296.8)
that were not accompanied by a unipolar depression or schizo-
phrenia claim on the same day, age between 10 and 64, and 1
year of continuous eligibility prior to and following the initial
bipolar diagnosis. RESULTS: Of the 3648 patients, 1859 (51%)
had sufﬁcient diagnostic information to identify the current
phase of the disorder. Of these 1859 patients, 69% were diag-
nosed during either a manic or mixed episode. Most frequently
the diagnostic claim was associated with a mental health spe-
cialist (64%), with only 7% being associated with a family or
general practitioner. The majority of index diagnoses were at
outpatient visits (75%), followed by inpatient hospitals (15%),
and Emergency Rooms (2%). On average, patients incurred
$9241 in paid claims per year, of which $2610 (28%) occurred
in the 2 weeks before and after the bipolar index date. During
this month surrounding initial diagnosis, hospitalizations
accounted for 72% of the costs. CONCLUSIONS: Bipolar dis-
order appears to be most commonly diagnosed at outpatient
visits by mental health specialists when symptoms of mania are
present. Earlier recognition and treatment may reduce the spike
in costs that surrounds the initial diagnosis.
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OBJECTIVE: To examine managed-care prescribing patterns for
patients beginning pharmacologic treatment in the depressive
phase of bipolar. METHODS: This retrospective study
(1995–2002) included a cohort of 1203 patients who had 3 con-
secutive years of data, received an ICD coded diagnosis of
bipolar depression and received one of four classes of psy-
chotropic medication (i.e. antidepressant, antipsychotic, benzo-
diazapine, or mood stabilizer). Treatment patterns were observed
for a one-year period post diagnosis. RESULTS: Seventy-seven
percent of extracted data was between 1999–2002. Fifty-ﬁve dif-
ferent medications were used to create multiple unique mono
and/or combination pharmacologic treatments. Nine percent of
patients began their treatment in accordance with APA guide-
lines, whereas, 16% began treatment using only an antidepres-
sant. As switches in treatment occur, use of mono-therapy
treatments decrease (-12%) and use of four or more medication
combinations increase (+9%). One third of patients were treated
with four or more medications in combination, at some point,
during the year following diagnosis. CONCLUSION: Pharma-
cologic treatment of bipolar depression is characterized by poly-
pharmacy, reﬂecting the complexity of the disorder; and is often
not aligned with guidelines. There is a need to study how these
patterns impact service utilization and costs, as well as to further
understand the treatment patterns.
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OBJECTIVES: To assess the construct validity and reliability of
the Center for Epidemiologic Studies Depression (CES-D) scale
in stroke patients, and to examine item functioning in depressed
stroke patients compared to generalized depression.
METHODS: Psychometric analyses were conducted on sec-
ondary data sources, including 101 patients 3, months post-
stroke (of whom 32 were depressed), and 366 individuals with
depression from the US general population. Presence of (poten-
tial) depression was based on a CES-D score ≥16. Convergent
validity of the CES-D scale in stroke patients was assessed with
concurrently administered measures—the SF-36 mental health
subscale (MH), and the Health Utilities Index Mark 2 and 3
single attribute utility score for emotion (HUI2-E, HUI3-E,
respectively)—using Spearman’s rank correlation coefﬁcients (r).
Internal consistency reliability was assessed using Cronbach’s a.
Rasch analysis was used to compare item hierarchies and to iden-
tify differential item functioning (DIF) between generalized
depression and depression after stroke. RESULTS: The CES-D
was strongly correlated with the MH subscale (r = -0.81), HUI2-
E (r = -0.71) and HUI3-E (r = -0.66). Internal consistency reli-
ability of the CES-D scale in stroke patients was satisfactory
(Cronbach’s a = 0.90). Rasch analysis identiﬁed several items that
were redundant or did not contribute to scale consistency. Item
hierarchies separated into similar strata of difﬁculty for
depressed stroke patients and generalized depression, with inter-
personal disruption items (people unfriendly, feeling disliked)
being the most difﬁcult to endorse in both samples. DIF between
generalized depression and stroke was identiﬁed on items relat-
ing to appetite, restless sleep, crying, and feeling disliked. CON-
